All News

2018

October

Media Release / Oct 23, 2018

Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed

Read More
Media Release / Oct 22, 2018

Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma

Read More
Media Release / Oct 20, 2018

Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone

Read More
Media Release / Oct 19, 2018

Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC

Read More
Media Release / Oct 19, 2018

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

Read More
Media Release / Oct 18, 2018

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms

Read More
Media Release / Oct 18, 2018

Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth

Read More
Novartis Financial Results – Q3 2018
Featured News / Oct 18, 2018

Novartis Financial Results – Q3 2018

Today, Novartis CEO Vas Narasimhan announced the company’s financial results for the third quarter of 2018.

Read More
Media Release / Oct 16, 2018

Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis

Read More
Media Release / Oct 11, 2018

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More